Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.
Background. Human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) respond to effective antituberculous therapy, but their prognosis remains poor. Mounting evidence from clinical studies supports the concept of copathogenesis in which immune activation that is triggered by TB and mediated by cytokines stimulates viral replication and worsens HIV infection, especially when immune function is preserved.Methods. We performed a phase 2, randomized, double-blind, placebo-controlled clinical trial in Kampala, Uganda, to determine whether immunoadjuvant prednisolone therapy in HIV-infected patients with TB who have CD4(+) T cell counts >/=200 cells/ mu L is safe and effective at increasing CD4(+) T cell counts.Results. Short-term prednisolone therapy reduced levels of immune activation and tended to produce higher CD4(+) T cell counts. Although prednisolone therapy was associated with a more rapid clearance of Mycobacterium tuberculosis from the sputum, it was also associated with a transient increase in HIV RNA levels, which receded when prednisolone therapy was discontinued. The intervention worsened underlying hypertension and caused fluid retention and hyperglycemia.Conclusion. The benefits of prednisolone therapy on immune activation and CD4(+) T cell counts do not outweigh the risks of adverse events in HIV-infected patients with TB and preserved immune function.
Mayanja-Kizza
Harriet
H
Department of Medicine, Makerere University Medical School, Kampala, Uganda.
Jones-Lopez
Edward
E
Okwera
Alphonse
A
Wallis
Robert S
RS
Ellner
Jerrold J
JJ
Mugerwa
Roy D
RD
Whalen
Christopher C
CC
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D012367:RNA, Viral; D011239:Prednisolone
Am Rev Respir Dis. 1992 Oct;146(4):849-54
1416409
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):361-6
9833744
BMC Med. 2004 May 05;2:17
15128452
Immunity. 1995 Jun;2(6):561-72
7540941
Virology. 1993 Jun;194(2):758-68
7684876
J Infect Dis. 1995 Mar;171(3):521-2
7876596
J Infect Dis. 1996 Oct;174(4):727-33
8843209
AIDS. 1993 Mar;7(3):375-8
8097096
Biometrics. 1982 Dec;38(4):963-74
7168798
J Infect Dis. 1993 Jan;167(1):43-8
8418182
N Engl J Med. 1991 Jan 31;324(5):289-94
1898769
Br J Cancer. 1977 Jan;35(1):1-39
831755
AIDS. 2000 Jun 16;14(9):1219-28
10894287
AIDS. 2004 Jan 23;18(2):257-64
15075543
J Infect Dis. 2004 Sep 1;190(5):869-78
15295690
Am Rev Respir Dis. 1991 Oct;144(4):750-5
1928943
J Infect Dis. 1995 Mar;171(3):523-30
7876597
MMWR Recomm Rep. 1998 Oct 30;47(RR-20):1-58
9809743
Am Rev Respir Dis. 1987 Sep;136(3):570-4
3631730
Science. 1995 Oct 13;270(5234):283-6
7569975
N Engl J Med. 2001 Oct 11;345(15):1098-104
11596589
Int J Tuberc Lung Dis. 2001 Mar;5(3):225-32
11326821
Int J Tuberc Lung Dis. 1997 Dec;1(6):582-4
9487460
Science. 1995 Oct 13;270(5234):286-90
7569976
Br Med J. 1960 Dec 17;2(5215):1751-6
13715890
Am J Respir Crit Care Med. 1995 Jan;151(1):129-35
7812542
Proc Natl Acad Sci U S A. 1990 Jan;87(2):782-5
2300561
AIDS. 1997 Mar 15;11(4):455-60
9084792
Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1977-81
8665064
Theor Popul Biol. 1999 Feb;55(1):94-109
9925811
Proc Natl Acad Sci U S A. 1989 Apr;86(7):2336-40
2494664
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Mar 1;11(3):247-57
8603261
Am Rev Respir Dis. 1993 Apr;147(4):958-61
8466133
JAMA. 1999 Aug 18;282(7):677-86
10517722
Chest. 1998 Nov;114(5):1258-63
9823998
J Infect Dis. 2003 Oct 15;188(8):1146-55
14551885
J Immunol. 1999 Mar 15;162(6):3504-11
10092807
J Infect Dis. 1992 Jan;165(1):1-13
1727879
Cell. 1989 Mar 10;56(5):731-40
2647299
J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):281-6
12626887
Am J Epidemiol. 1997 Feb 15;145(4):293-300
9054232
AIDS. 1999 Jul 9;13(10):1151-8
10416517
Ann Intern Med. 1989 Jun 1;110(11):937-40
2719427